Athyrium Capital Management
Latest statistics and disclosures from Athyrium Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AMYT, Progenity, Omeros Corp, RVLP, Omeros Corp note 6.250%11/1, and represent 93.68% of Athyrium Capital Management's stock portfolio.
- Added to shares of these 2 stocks: Omeros Corp (+$5.0M), Biora Therapeutics Ord.
- Started 1 new stock positions in Biora Therapeutics Ord.
- Reduced shares in these 5 stocks: CMAX (-$16M), Omeros Corp note 6.250%11/1 (-$10M), Bridgebio Pharma (-$7.8M), Progenity (-$5.6M), SCTL.
- Sold out of its positions in Bridgebio Pharma, CMAX, Progenity, SCTL.
- Athyrium Capital Management was a net seller of stock by $-33M.
- Athyrium Capital Management has $279M in assets under management (AUM), dropping by 17.31%.
- Central Index Key (CIK): 0001728001
Tip: Access up to 7 years of quarterly data
Positions held by Athyrium Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Athyrium Capital Management
Athyrium Capital Management holds 8 positions in its portfolio as reported in the March 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Amryt Pharma Sponsored ADS (AMYT) | 46.3 | $129M | 8.9M | 14.58 |
|
|
| Biora Note 7.250% 12/0 (Principal) | 20.8 | $58M | 104M | 0.56 |
|
|
| Omeros Corp Note 5.250% 2/1 (Principal) | 16.7 | $47M | +12% | 65M | 0.71 |
|
| Rvl Pharmaceuticals SHS (RVLP) | 6.0 | $17M | 15M | 1.14 |
|
|
| Omeros Corp Note 6.250%11/1 (Principal) | 4.0 | $11M | -47% | 11M | 1.01 |
|
| Paratek Pharmaceuticals Note 4.750% 5/0 (Principal) | 2.7 | $7.4M | 9.0M | 0.82 |
|
|
| Puma Biotechnology (PBYI) | 2.0 | $5.5M | 1.8M | 3.09 |
|
|
| Biora Therapeutics Ord | 1.7 | $4.7M | NEW | 1.7M | 2.77 |
|
Past Filings by Athyrium Capital Management
SEC 13F filings are viewable for Athyrium Capital Management going back to 2017
- Athyrium Capital Management 2023 Q1 restated filed May 16, 2023
- Athyrium Capital Management 2022 Q4 filed Feb. 14, 2023
- Athyrium Capital Management 2022 Q3 filed Nov. 14, 2022
- Athyrium Capital Management 2022 Q2 filed Aug. 15, 2022
- Athyrium Capital Management 2022 Q1 filed May 16, 2022
- Athyrium Capital Management 2021 Q4 filed Feb. 14, 2022
- Athyrium Capital Management 2021 Q3 filed Nov. 15, 2021
- Athyrium Capital Management 2021 Q2 filed Aug. 16, 2021
- Athyrium Capital Management 2021 Q1 filed May 17, 2021
- Athyrium Capital Management 2020 Q4 filed Feb. 16, 2021
- Athyrium Capital Management 2019 Q3 filed Nov. 14, 2019
- Athyrium Capital Management 2019 Q2 filed Aug. 14, 2019
- Athyrium Capital Management 2019 Q1 filed May 15, 2019
- Athyrium Capital Management 2018 Q4 filed Feb. 12, 2019
- Athyrium Capital Management 2018 Q3 filed Nov. 13, 2018
- Athyrium Capital Management 2018 Q2 filed Aug. 14, 2018